IONIS PHARMACEUTICALS INC (IONS)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $1.7M
- Jul 7 · Routine
- Form 4 sales
- 681
- On record
- Form 144 notices
- 61
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleUnusualJun 26 2026
Sold 85,637 shares at $79.70 ($6.8M)
Monia Brett P, Chief Executive Officer
10b5-1 planSold 25.9% of holdings ($26.4M position)245,571 shares left4x usual sizeFiling
- 2 Form 4 saleUnusualJun 26 same day
Sold 26,000 shares at $81.05 ($2.1M)
Schneider Eugene, EVP, Chf Clinical Develop Ofcr
10b5-1 planSold 25.2% of holdings ($8.4M position)77,114 shares left4x usual sizeFiling
- 3 Form 4 saleRoutineJun 26 same day
Sold 3,069 shares at $80.00 ($246k)
O'Neil Patrick R., EVP CLO & General Counsel
10b5-1 planSold 4.8% of holdings ($5.2M position)61,470 shares left0.3x usual sizeFiling
- 4 Form 4 saleRoutineJun 26 same day
Sold 5,635 shares at $80.16 ($452k)
Baroldi Joseph, EVP, Chief Business Officer
10b5-1 planSold 54.7% of holdings ($826k position)4,669 shares left1x usual sizeFiling
- 5 Form 4 saleRoutineJul 1 +5 days
Sold 11,518 shares at $79.04 ($910k)
Klein Joseph III, Director
10b5-1 planSold 51.1% of holdings ($1.8M position)11,014 shares left0.5x usual sizeFiling
- 6 Form 4 saleRoutineJul 7 +6 days
Sold 362 shares at $84.30 ($31k)
Kordasiewicz Holly B., EVP, Chief Development Officer
10b5-1 planSold 1.6% of holdings ($1.9M position)22,096 shares leftFiling
- 7 Form 4 saleUnusualJul 7 same day
Sold 10,111 shares at $85.42 ($864k)
Diaz Allene M., Director
10b5-1 planSold 72.6% of holdings ($1.2M position)3,811 shares left6.2x usual sizeFiling
- 8 Form 4 saleRoutineJul 7 same day
Sold 20,536 shares at $84.95 ($1.7M)
Bennett C Frank, EVP, Chief Scientific Officer
10b5-1 planSold 21.5% of holdings ($8.1M position)75,018 shares left2.3x usual sizeFiling
Every transaction
Loading transactions…
Sales, notices and lockups (newest 400 of 742)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 20,536 | $1.7M | 21.5% | Routine | SEC |
| Jul 7, 2026 | Diaz Allene M. | Director | Form 4 sale | 10,111 | $864k | 72.6% | Unusual | SEC |
| Jul 7, 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | Form 4 sale | 362 | $31k | 1.6% | Routine | SEC |
| Jul 1, 2026 | Klein Joseph III | Director | Form 4 sale | 11,518 | $910k | 51.1% | Routine | SEC |
| Jun 26, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 5,635 | $452k | 54.7% | Routine | SEC |
| Jun 26, 2026 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 3,069 | $246k | 4.8% | Routine | SEC |
| Jun 26, 2026 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Form 4 sale | 26,000 | $2.1M | 25.2% | Unusual | SEC |
| Jun 26, 2026 | Monia Brett P | Chief Executive Officer | Form 4 sale | 85,637 | $6.8M | 25.9% | Unusual | SEC |
| Jun 25, 2026 | Swayze Eric | EVP Research | Form 4 sale | 10,602 | $839k | 32.8% | Routine | SEC |
| Jun 15, 2026 | Berthelsen Spencer R | Director | Form 4 sale | 8,000 | $588k | 4.9% | Routine | SEC |
| Jun 12, 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | Form 4 sale | 60,846 | $4.5M | 73.0% | Routine | SEC |
| Jun 1, 2026 | Berthelsen Spencer R | Director | Form 4 sale | 8,000 | $605k | 4.9% | Routine | SEC |
| May 14, 2026 | Monia Brett P | Chief Executive Officer | Form 4 sale | 4,536 | $356k | 1.8% | Routine | SEC |
| May 4, 2026 | Loscalzo Joseph | Director | Form 4 sale | 77,289 | $5.8M | 68.0% | Unusual | SEC |
| May 1, 2026 | Klein Joseph III | Director | Form 4 sale | 10,111 | $743k | 47.9% | Routine | SEC |
| Apr 28, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 1,626 | $117k | 3.5% | Routine | SEC |
| Apr 16, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | Form 4 sale | 4,902 | $368k | 17.1% | No plan | SEC |
| Apr 16, 2026 | Birchler Brian | EVP, Corp and Development Ops | Form 4 sale | 973 | $73k | 1.4% | No plan | SEC |
| Apr 16, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 5,619 | $419k | 10.8% | No plan | SEC |
| Apr 15, 2026 | Parshall B Lynne | Director | Form 4 sale | 5,000 | $381k | 8.9% | Routine | SEC |
| Apr 2, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Form 4 sale | 6,193 | $459k | 27.5% | Routine | SEC |
| Apr 1, 2026 | Klein Joseph III | Director | Form 4 sale | 22,321 | $1.7M | 67.0% | Routine | SEC |
| Mar 19, 2026 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Form 4 sale | 5,812 | $412k | 8.3% | Routine | SEC |
| Mar 17, 2026 | Hougen Elizabeth L | EVP, Finance & CFO | Form 4 sale | 225,220 | $16.3M | 73.2% | Unusual | SEC |
| Mar 10, 2026 | Monia Brett P | Chief Executive Officer | Form 4 sale | 160,773 | $12.1M | 39.9% | Unusual | SEC |
| Mar 10, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | Form 4 sale | 37,277 | $2.8M | 76.1% | Routine | SEC |
| Mar 9, 2026 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 10,148 | $764k | 14.0% | Routine | SEC |
| Mar 4, 2026 | Loscalzo Joseph | Director | Form 4 sale | 1,032 | $83k | 2.8% | Routine | SEC |
| Mar 4, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 6,659 | $531k | 13.9% | Routine | SEC |
| Mar 3, 2026 | Klein Joseph III | Director | Form 4 sale | 21,332 | $1.7M | 65.9% | Routine | SEC |
| Mar 3, 2026 | Diaz Allene M. | Director | Form 4 sale | 54,878 | $4.4M | 93.5% | Routine | SEC |
| Mar 3, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Form 4 sale | 20,106 | $1.6M | 47.1% | Routine | SEC |
| Mar 3, 2026 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 85,089 | $6.7M | 51.4% | Unusual | SEC |
| Feb 13, 2026 | Swayze Eric | EVP Research | Form 4 sale | 15,642 | $1.3M | 32.8% | Routine | SEC |
| Feb 11, 2026 | Parshall B Lynne | Director | Form 4 sale | 5,000 | $414k | 8.2% | Routine | SEC |
| Feb 6, 2026 | Monia Brett P | Chief Executive Officer | Form 4 sale | 29,430 | $2.5M | 10.4% | Routine | SEC |
| Feb 2, 2026 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 85,089 | $7.1M | 51.4% | Unusual | SEC |
| Jan 30, 2026 | Swayze Eric | EVP Research | Form 4 sale | 6,179 | $512k | 11.5% | No plan | SEC |
| Jan 30, 2026 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Form 4 sale | 6,179 | $516k | 8.1% | No plan | SEC |
| Jan 30, 2026 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 6,179 | $516k | 7.9% | No plan | SEC |
| Jan 30, 2026 | Monia Brett P | Chief Executive Officer | Form 4 sale | 62,970 | $5.2M | 18.2% | Unusual | SEC |
| Jan 30, 2026 | Hougen Elizabeth L | EVP, Finance & CFO | Form 4 sale | 6,988 | $582k | 5.0% | No plan | SEC |
| Jan 30, 2026 | Birchler Brian | EVP, Corp and Development Ops | Form 4 sale | 6,179 | $513k | 8.5% | No plan | SEC |
| Jan 30, 2026 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 5,885 | $488k | 5.5% | No plan | SEC |
| Jan 30, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 5,296 | $439k | 10.4% | No plan | SEC |
| Jan 22, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Form 4 sale | 3,977 | $323k | 15.0% | Routine | SEC |
| Jan 16, 2026 | Swayze Eric | EVP Research | Form 4 sale | 9,933 | $748k | 19.2% | No plan | SEC |
| Jan 16, 2026 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Form 4 sale | 9,302 | $703k | 12.7% | No plan | SEC |
| Jan 16, 2026 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 9,191 | $697k | 12.2% | No plan | SEC |
| Jan 16, 2026 | Monia Brett P | Chief Executive Officer | Form 4 sale | 44,034 | $3.3M | 16.4% | Unusual | SEC |
| Jan 16, 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | Form 4 sale | 4,141 | $313k | 22.0% | No plan | SEC |
| Jan 16, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | Form 4 sale | 1,823 | $138k | 10.0% | No plan | SEC |
| Jan 16, 2026 | Hougen Elizabeth L | EVP, Finance & CFO | Form 4 sale | 12,922 | $972k | 9.3% | No plan | SEC |
| Jan 16, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Form 4 sale | 8,353 | $634k | 24.0% | No plan | SEC |
| Jan 16, 2026 | Birchler Brian | EVP, Corp and Development Ops | Form 4 sale | 8,480 | $637k | 12.3% | No plan | SEC |
| Jan 16, 2026 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 8,977 | $675k | 8.7% | No plan | SEC |
| Jan 16, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 8,056 | $610k | 16.6% | No plan | SEC |
| Jan 7, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Form 4 sale | 44,199 | $3.8M | 71.6% | Unusual | SEC |
| Jan 2, 2026 | Swayze Eric | EVP Research | Form 4 sale | 23,463 | $1.9M | 43.5% | Unusual | SEC |
| Dec 1, 2025 | Wender Joseph H | Director | Form 4 sale | 28,000 | $2.3M | 43.7% | Routine | SEC |
| Nov 25, 2025 | Klein Joseph III | Director | Form 4 sale | 12,000 | $960k | 100.0% | Routine | SEC |
| Nov 25, 2025 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Form 4 sale | 16,777 | $1.4M | 49.0% | Unusual | SEC |
| Nov 19, 2025 | Herman Joan E | Director | Form 4 sale | 44,000 | $3.2M | 48.8% | Unusual | SEC |
| Nov 6, 2025 | Birchler Brian | EVP, Corp and Development Ops | Form 4 sale | 8,000 | $609k | 14.1% | Routine | SEC |
| Nov 6, 2025 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 34,639 | $2.6M | 36.7% | Unusual | SEC |
| Nov 3, 2025 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 90,929 | $6.8M | 60.4% | Unusual | SEC |
| Oct 31, 2025 | Wender Joseph H | Director | Form 4 sale | 28,000 | $2.1M | 30.4% | Routine | SEC |
| Oct 31, 2025 | Loscalzo Joseph | Director | Form 4 sale | 16,000 | $1.2M | 30.6% | Routine | SEC |
| Oct 16, 2025 | Swayze Eric | EVP Research | Form 4 sale | 53 | $4k | 17.2% | No plan | SEC |
| Oct 16, 2025 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Form 4 sale | 7,263 | $531k | 29.3% | Routine | SEC |
| Oct 15, 2025 | Parshall B Lynne | Director | Form 4 sale | 5,000 | $359k | 7.5% | Routine | SEC |
| Oct 15, 2025 | Birchler Brian | EVP, Corp and Development Ops | Form 4 sale | 23,900 | $1.7M | 29.6% | Unusual | SEC |
| Oct 6, 2025 | Swayze Eric | EVP Research | Form 4 sale | 6,849 | $473k | 18.4% | Routine | SEC |
| Oct 6, 2025 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 13,441 | $937k | 20.0% | Routine | SEC |
| Oct 6, 2025 | Monia Brett P | Chief Executive Officer | Form 4 sale | 437 | $30k | 0.2% | Routine | SEC |
| Oct 6, 2025 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 1,625 | $113k | 5.1% | Routine | SEC |
| Oct 2, 2025 | Swayze Eric | EVP Research | Form 4 sale | 27,114 | $1.8M | 42.1% | Unusual | SEC |
| Oct 2, 2025 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 64,664 | $4.4M | 53.1% | Unusual | SEC |
| Oct 2, 2025 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 15,000 | $1M | 32.0% | Unusual | SEC |
| Oct 1, 2025 | Wender Joseph H | Director | Form 4 sale | 16,800 | $1.1M | 15.4% | Routine | SEC |
| Sep 30, 2025 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 25,300 | $1.6M | 30.7% | Unusual | SEC |
| Sep 30, 2025 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 57,900 | $3.8M | 42.1% | Unusual | SEC |
| Sep 30, 2025 | Hougen Elizabeth L | EVP, Finance & CFO | Form 4 sale | 49,800 | $3.2M | 31.1% | Unusual | SEC |
| Sep 12, 2025 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 1,700 | $110k | 2.9% | Routine | SEC |
| Sep 9, 2025 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 11,950 | $743k | 27.2% | Unusual | SEC |
| Sep 9, 2025 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 21,000 | $1.4M | 26.9% | Unusual | SEC |
| Sep 5, 2025 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 250 | $16k | 0.8% | Routine | SEC |
| Sep 5, 2025 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 6,000 | $358k | 6.8% | Routine | SEC |
| Sep 3, 2025 | Wender Joseph H | Director | Form 4 sale | 28,000 | $1.6M | 20.5% | Routine | SEC |
| Sep 3, 2025 | Monia Brett P | Chief Executive Officer | Form 4 sale | 203,814 | $12.3M | 53.1% | Unusual | SEC |
| Sep 3, 2025 | Klein Joseph III | Director | Form 4 sale | 28,000 | $1.7M | 100.0% | Unusual | SEC |
| Sep 3, 2025 | Klein Joseph III | Director | Form 4 sale | 28,000 | $1.7M | 100.0% | Unusual | SEC |
| Sep 3, 2025 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Form 4 sale | 3,162 | $193k | 17.4% | Routine | SEC |
| Sep 3, 2025 | Wender Joseph H | Director | Form 4 sale | 28,000 | $1.6M | 20.5% | Routine | SEC |
| Sep 3, 2025 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 32,800 | $1.9M | 66.0% | Unusual | SEC |
| Sep 3, 2025 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 89,900 | $5.4M | 92.5% | Unusual | SEC |
| Sep 3, 2025 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 38,909 | $2.3M | 27.7% | Unusual | SEC |
| Sep 3, 2025 | Loscalzo Joseph | Director | Form 4 sale | 16,000 | $962k | 30.6% | Unusual | SEC |
| Sep 3, 2025 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Form 4 sale | 19,658 | $1.2M | 27.6% | Unusual | SEC |
| Sep 2, 2025 | Swayze Eric | EVP Research | Form 4 sale | 11,130 | $553k | 23.0% | Routine | SEC |
| Sep 2, 2025 | Parshall B Lynne | Director | Form 4 sale | 20,000 | $1M | 23.2% | Routine | SEC |
| Sep 2, 2025 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 10,000 | $504k | 11.2% | Routine | SEC |
| Aug 22, 2025 | Diaz Allene M. | Director | Form 4 sale | 1,427 | $61k | 7.2% | Routine | SEC |
| Aug 18, 2025 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 10,000 | $440k | 9.7% | Routine | SEC |
| Aug 6, 2025 | Parshall B Lynne | Director | Form 4 sale | 5,000 | $210k | 5.5% | Routine | SEC |
| Aug 5, 2025 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 10,000 | $429k | 10.1% | Routine | SEC |
| Aug 4, 2025 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Form 4 sale | 9,549 | $409k | 15.6% | Routine | SEC |
| Jul 30, 2025 | Monia Brett P | Chief Executive Officer | Form 4 sale | 2,432 | $109k | 1.3% | Routine | SEC |
| Jul 11, 2025 | Monia Brett P | Chief Executive Officer | Form 4 sale | 1,160 | $48k | 0.6% | Routine | SEC |
| Apr 16, 2025 | Birchler Brian | EVP, Corp and Development Ops | Form 4 sale | 680 | $19k | 1.2% | No plan | SEC |
| Apr 16, 2025 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | Form 4 sale | 3,016 | $86k | 21.2% | No plan | SEC |
| Apr 16, 2025 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 3,928 | $112k | 11.0% | No plan | SEC |
| Mar 11, 2025 | Monia Brett P | Chief Executive Officer | Form 4 sale | 140 | $5k | 0.1% | Routine | SEC |
| Feb 20, 2025 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 1,207 | $39k | 2.1% | Routine | SEC |
| Feb 4, 2025 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 6,165 | $195k | 9.7% | Routine | SEC |
| Feb 4, 2025 | Monia Brett P | Chief Executive Officer | Form 4 sale | 38,843 | $1.2M | 17.7% | Routine | SEC |
| Jan 31, 2025 | Swayze Eric | EVP Research | Form 4 sale | 1,367 | $44k | 2.8% | No plan | SEC |
| Jan 31, 2025 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Form 4 sale | 1,484 | $48k | 2.4% | No plan | SEC |
| Jan 31, 2025 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 1,406 | $46k | 2.2% | No plan | SEC |
| Jan 31, 2025 | Monia Brett P | Chief Executive Officer | Form 4 sale | 13,242 | $430k | 5.7% | No plan | SEC |
| Jan 31, 2025 | Hougen Elizabeth L | EVP, Finance & CFO | Form 4 sale | 1,523 | $49k | 1.4% | No plan | SEC |
| Jan 31, 2025 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 1,406 | $46k | 1.4% | No plan | SEC |
| Jan 31, 2025 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 1,327 | $43k | 1.4% | No plan | SEC |
| Jan 16, 2025 | Swayze Eric | EVP Research | Form 4 sale | 7,176 | $236k | 13.6% | No plan | SEC |
| Jan 16, 2025 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Form 4 sale | 6,523 | $214k | 10.0% | No plan | SEC |
| Jan 16, 2025 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 7,360 | $242k | 10.7% | No plan | SEC |
| Jan 16, 2025 | Monia Brett P | Chief Executive Officer | Form 4 sale | 33,445 | $1.1M | 13.9% | No plan | SEC |
| Jan 16, 2025 | Hougen Elizabeth L | EVP, Finance & CFO | Form 4 sale | 8,870 | $291k | 7.6% | No plan | SEC |
| Jan 16, 2025 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 7,072 | $232k | 6.8% | No plan | SEC |
| Jan 16, 2025 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Form 4 sale | 4,267 | $140k | 21.1% | No plan | SEC |
| Jan 16, 2025 | Birchler Brian | EVP, Corp and Development Ops | Form 4 sale | 5,400 | $177k | 8.9% | Unusual | SEC |
| Jan 16, 2025 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 6,752 | $222k | 6.9% | No plan | SEC |
| Jan 16, 2025 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 4,430 | $145k | 15.0% | No plan | SEC |
| Nov 12, 2024 | Swayze Eric | EVP Research | Form 4 sale | 1,194 | $45k | 3.4% | Routine | SEC |
| Nov 12, 2024 | Monia Brett P | Chief Executive Officer | Form 4 sale | 6,630 | $252k | 3.8% | Routine | SEC |
| Nov 12, 2024 | Loscalzo Joseph | Director | Form 4 sale | 13,508 | $511k | 29.5% | Routine | SEC |
| Oct 16, 2024 | Swayze Eric | EVP Research | Form 4 sale | 53 | $2k | 25.2% | Unusual | SEC |
| Aug 29, 2024 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 651 | $32k | 0.8% | Routine | SEC |
| Aug 5, 2024 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 2,430 | $117k | 2.8% | Routine | SEC |
| Jul 16, 2024 | Klein Joseph III | Director | Form 4 sale | 12,000 | $600k | 100.0% | Unusual | SEC |
| Jul 16, 2024 | Diaz Allene M. | Director | Form 4 sale | 1,637 | $81k | 9.4% | Routine | SEC |
| Jun 17, 2024 | Berthelsen Spencer R | Director | Form 4 sale | 16,000 | $645k | 9.8% | Routine | SEC |
| May 3, 2024 | Klein Joseph III | Director | Form 4 sale | 6,000 | $256k | 100.0% | Unusual | SEC |
| Apr 16, 2024 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 4,006 | $167k | 16.9% | No plan | SEC |
| Apr 16, 2024 | Birchler Brian | EVP, Corp and Development Ops | Form 4 sale | 905 | $38k | 1.9% | No plan | SEC |
| Feb 16, 2024 | Monia Brett P | Officer, Director | Form 144 notice | 387 | $17k | Notice | SEC | |
| Feb 16, 2024 | Monia Brett P | Chief Executive Officer | Form 4 sale | 387 | $17k | 0.2% | Routine | SEC |
| Feb 2, 2024 | Monia Brett P | Officer, Director | Form 144 notice | 23,501 | $1.2M | Notice | SEC | |
| Feb 2, 2024 | Swayze Eric | Officer | Form 144 notice | 1,907 | $95k | Notice | SEC | |
| Feb 2, 2024 | Schneider Eugene | Officer | Form 144 notice | 2,071 | $103k | Notice | SEC | |
| Feb 2, 2024 | Geary Richard S | Officer | Form 144 notice | 1,961 | $98k | Notice | SEC | |
| Feb 2, 2024 | Hougen Elizabeth L | Officer | Form 144 notice | 2,125 | $105k | Notice | SEC | |
| Feb 2, 2024 | O'Neil Patrick R. | Officer | Form 144 notice | 1,961 | $97k | Notice | SEC | |
| Feb 2, 2024 | Cadoret-Manier Onaiza | Officer | Form 144 notice | 2,125 | $105k | Notice | SEC | |
| Feb 2, 2024 | Bennett C Frank | Officer | Form 144 notice | 1,853 | $92k | Notice | SEC | |
| Feb 2, 2024 | Swayze Eric | EVP Research | Form 4 sale | 12,680 | $655k | 27.0% | Unusual | SEC |
| Feb 2, 2024 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Form 4 sale | 2,071 | $103k | 4.0% | No plan | SEC |
| Feb 2, 2024 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 1,961 | $97k | 3.9% | No plan | SEC |
| Feb 2, 2024 | Monia Brett P | Chief Executive Officer | Form 4 sale | 23,501 | $1.2M | 11.9% | No plan | SEC |
| Feb 2, 2024 | Hougen Elizabeth L | EVP, Finance & CFO | Form 4 sale | 2,125 | $105k | 2.2% | No plan | SEC |
| Feb 2, 2024 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 1,961 | $98k | 2.2% | No plan | SEC |
| Feb 2, 2024 | Cadoret-Manier Onaiza | EVP, Chf GL Pdt Str & Oper Ofc | Form 4 sale | 2,125 | $105k | 5.6% | No plan | SEC |
| Feb 2, 2024 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 1,853 | $92k | 2.3% | No plan | SEC |
| Jan 31, 2024 | Swayze Eric | Officer | Form 144 notice | 10,773 | $560k | Notice | SEC | |
| Jan 26, 2024 | Monia Brett P | Officer, Director | Form 144 notice | 2,285 | $118k | Notice | SEC | |
| Jan 26, 2024 | O'Neil Patrick R. | Officer | Form 144 notice | 6,450 | $334k | Notice | SEC | |
| Jan 25, 2024 | Monia Brett P | Chief Executive Officer | Form 4 sale | 2,285 | $118k | 1.5% | Routine | SEC |
| Jan 25, 2024 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 6,450 | $334k | 12.1% | Routine | SEC |
| Jan 17, 2024 | Cadoret-Manier Onaiza | EVP, Chf GL Pdt Str & Oper Ofc | Form 4 sale | 5,564 | $281k | 14.1% | No plan | SEC |
| Jan 17, 2024 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 7,744 | $390k | 12.7% | No plan | SEC |
| Jan 17, 2024 | Birchler Brian | EVP, Corp and Development Ops | Form 4 sale | 4,497 | $227k | 9.2% | No plan | SEC |
| Jan 17, 2024 | Swayze Eric | EVP Research | Form 4 sale | 6,305 | $318k | 12.7% | Unusual | SEC |
| Jan 17, 2024 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Form 4 sale | 5,482 | $276k | 10.3% | No plan | SEC |
| Jan 17, 2024 | Monia Brett P | Chief Executive Officer | Form 4 sale | 32,059 | $1.6M | 17.2% | No plan | SEC |
| Jan 17, 2024 | Hougen Elizabeth L | EVP, Finance & CFO | Form 4 sale | 8,683 | $438k | 8.7% | No plan | SEC |
| Jan 17, 2024 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 7,338 | $370k | 7.9% | No plan | SEC |
| Jan 17, 2024 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 6,745 | $340k | 8.0% | No plan | SEC |
| Jan 17, 2024 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 2,024 | $102k | 13.7% | No plan | SEC |
| Jan 17, 2024 | O'Neil Patrick R. | Officer | Form 144 notice | 7,645 | $405k | Notice | SEC | |
| Jan 17, 2024 | Monia Brett P | Officer, Director | Form 144 notice | 32,059 | $1.6M | Notice | SEC | |
| Jan 17, 2024 | Schneider Eugene | Officer | Form 144 notice | 5,482 | $277k | Notice | SEC | |
| Jan 17, 2024 | Cadoret-Manier Onaiza | Officer | Form 144 notice | 5,564 | $281k | Notice | SEC | |
| Jan 17, 2024 | Bennett C Frank | Officer | Form 144 notice | 6,745 | $341k | Notice | SEC | |
| Jan 17, 2024 | Hougen Elizabeth L | Officer | Form 144 notice | 8,683 | $439k | Notice | SEC | |
| Jan 17, 2024 | Geary Richard S | Officer | Form 144 notice | 7,338 | $371k | Notice | SEC | |
| Jan 17, 2024 | Swayze Eric | Officer | Form 144 notice | 6,296 | $31.8M | Notice | SEC | |
| Jan 17, 2024 | Birchler Brian | Officer | Form 144 notice | 4,497 | $227k | Notice | SEC | |
| Jan 16, 2024 | Baroldi Joseph | Officer | Form 144 notice | 1,460 | $74k | Notice | SEC | |
| Jan 12, 2024 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Form 4 sale | 8,000 | $428k | 17.3% | Routine | SEC |
| Jan 12, 2024 | Schneider Eugene | Officer | Form 144 notice | 8,000 | $428k | Notice | SEC | |
| Dec 28, 2023 | Swayze Eric | EVP Research | Form 4 sale | 27,100 | $1.4M | 45.5% | Unusual | SEC |
| Dec 28, 2023 | Swayze Eric | Officer | Form 144 notice | 27,100 | $1.4M | Notice | SEC | |
| Dec 28, 2023 | Parshall B Lynne | Director | Form 4 sale | 117,638 | $5.9M | 58.8% | Routine | SEC |
| Dec 27, 2023 | Schneider Eugene | Officer | Form 144 notice | 25,000 | $1.3M | Notice | SEC | |
| Dec 27, 2023 | O'Neil Patrick R. | Officer | Form 144 notice | 20,825 | $1.1M | Notice | SEC | |
| Dec 26, 2023 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 20,825 | $1.1M | 34.0% | Unusual | SEC |
| Dec 26, 2023 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Form 4 sale | 25,000 | $1.3M | 40.9% | Routine | SEC |
| Dec 26, 2023 | Parshall B Lynne | Director | Form 144 notice | 117,638 | $6.1M | Notice | SEC | |
| Dec 22, 2023 | Monia Brett P | Officer, Director | Form 144 notice | 24,000 | $1.2M | Notice | SEC | |
| Dec 22, 2023 | Geary Richard S | Officer | Form 144 notice | 10,612 | $525k | Notice | SEC | |
| Dec 22, 2023 | Bennett C Frank | Officer | Form 144 notice | 22,613 | $1.1M | Notice | SEC | |
| Dec 21, 2023 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 22,613 | $1.1M | 25.6% | Unusual | SEC |
| Dec 21, 2023 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 10,612 | $525k | 12.7% | Routine | SEC |
| Dec 21, 2023 | Monia Brett P | Chief Executive Officer | Form 4 sale | 24,000 | $1.2M | 16.9% | Routine | SEC |
| Dec 15, 2023 | Monia Brett P | Officer, Director | Form 144 notice | 10,613 | $526k | Notice | SEC | |
| Dec 15, 2023 | Geary Richard S | Officer | Form 144 notice | 24,000 | $1.2M | Notice | SEC | |
| Dec 15, 2023 | Bennett C Frank | Officer | Form 144 notice | 22,612 | $1.1M | Notice | SEC | |
| Dec 14, 2023 | Monia Brett P | Chief Executive Officer | Form 4 sale | 24,000 | $1.2M | 16.9% | Routine | SEC |
| Dec 14, 2023 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 10,613 | $526k | 12.7% | Routine | SEC |
| Dec 14, 2023 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 22,612 | $1.1M | 25.6% | Unusual | SEC |
| Nov 15, 2023 | Klein Joseph III | Director | Form 4 sale | 2,000 | $100k | 10.9% | Routine | SEC |
| Nov 15, 2023 | Klein Joseph III | Director | Form 144 notice | 2,000 | $100k | Notice | SEC | |
| Oct 17, 2023 | Swayze Eric | EVP Research | Form 4 sale | 52 | $2k | 41.6% | Unusual | SEC |
| Oct 12, 2023 | Monia Brett P | Chief Executive Officer | Form 4 sale | 3,770 | $173k | 3.1% | Routine | SEC |
| Oct 12, 2023 | Monia Brett P | Officer, Director | Form 144 notice | 3,770 | $173k | Notice | SEC | |
| Sep 29, 2023 | Bennett C Frank | Officer | Form 144 notice | 4,460 | $207k | Notice | SEC | |
| Sep 28, 2023 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 4,460 | $207k | 6.4% | Routine | SEC |
| Sep 26, 2023 | Parshall B Lynne | Director | Form 4 sale | 10,000 | $451k | 10.8% | Routine | SEC |
| Sep 26, 2023 | Klein Joseph III | Director | Form 4 sale | 2,000 | $90k | 9.8% | Routine | SEC |
| Sep 26, 2023 | Parshall B Lynne | Director | Form 144 notice | 10,000 | $451k | Notice | SEC | |
| Sep 26, 2023 | Klein Joseph III | Director | Form 144 notice | 2,000 | $90k | Notice | SEC | |
| Aug 2, 2023 | Diaz Allene M. | Director | Form 144 notice | 657 | $27k | Notice | SEC | |
| Aug 1, 2023 | Diaz Allene M. | Director | Form 4 sale | 657 | $27k | 4.9% | Routine | SEC |
| Jul 19, 2023 | Klein Joseph III | Director | Form 144 notice | 3,555 | $149k | Notice | SEC | |
| Jul 18, 2023 | Klein Joseph III | Director | Form 4 sale | 3,555 | $149k | 14.9% | No plan | SEC |
| Jul 7, 2023 | Monia Brett P | Chief Executive Officer | Form 4 sale | 18,650 | $788k | 13.3% | Routine | SEC |
| Jul 7, 2023 | Monia Brett P | Officer, Director | Form 144 notice | 18,650 | $788k | Notice | SEC | |
| May 24, 2023 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 1,527 | $64k | 3.6% | Routine | SEC |
| May 24, 2023 | O'Neil Patrick R. | Officer | Form 144 notice | 1,527 | $64k | Notice | SEC | |
| May 22, 2023 | Monia Brett P | Chief Executive Officer | Form 4 sale | 4,931 | $198k | 3.4% | Routine | SEC |
| May 22, 2023 | Monia Brett P | Officer, Director | Form 144 notice | 4,931 | $198k | Notice | SEC | |
| May 22, 2023 | Insight Securities, INC. | Officer | Form 144 notice | 4,931 | $198k | Notice | SEC | |
| Apr 18, 2023 | Birchler Brian | EVP, Corp and Development Ops | Form 4 sale | 672 | $25k | 1.8% | No plan | SEC |
| Apr 18, 2023 | Cadoret-Manier Onaiza | EVP, Chf GL Pdt Str & Oper Ofc | Form 4 sale | 2,582 | $94k | 9.6% | No plan | SEC |
| Apr 18, 2023 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 3,880 | $142k | 26.8% | Unusual | SEC |
| Apr 17, 2023 | Cadoret-Manier Onaiza | Officer | Form 144 notice | 2,743 | $104k | Notice | SEC | |
| Apr 17, 2023 | Birchler Brian | Officer | Form 144 notice | 713 | $27k | Notice | SEC | |
| Apr 17, 2023 | Baroldi Joseph | Officer | Form 144 notice | 4,122 | $156k | Notice | SEC | |
| Feb 6, 2023 | Swayze Eric | EVP Research | Form 4 sale | 1,815 | $74k | 5.4% | Unusual | SEC |
| Feb 6, 2023 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Form 4 sale | 1,413 | $57k | 5.4% | Plan not stated | SEC |
| Feb 6, 2023 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 1,920 | $78k | 4.4% | Plan not stated | SEC |
| Feb 6, 2023 | Monia Brett P | Chief Executive Officer | Form 4 sale | 24,651 | $1M | 14.5% | Unusual | SEC |
| Feb 6, 2023 | Hougen Elizabeth L | EVP, Finance & CFO | Form 4 sale | 2,079 | $84k | 2.7% | Plan not stated | SEC |
| Feb 6, 2023 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 1,920 | $78k | 2.6% | Plan not stated | SEC |
| Feb 6, 2023 | Cadoret-Manier Onaiza | EVP, Chf GL Pdt Str & Oper Ofc | Form 4 sale | 1,451 | $59k | 6.4% | Plan not stated | SEC |
| Feb 6, 2023 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 1,813 | $74k | 2.5% | Plan not stated | SEC |
| Feb 6, 2023 | Swayze Eric | Officer | Form 144 notice | 1,815 | $74k | Notice | SEC | |
| Feb 6, 2023 | Schneider Eugene | Officer | Form 144 notice | 1,413 | $57k | Notice | SEC | |
| Feb 6, 2023 | Monia Brett P | Officer, Director | Form 144 notice | 24,651 | $1M | Notice | SEC | |
| Feb 6, 2023 | Hougen Elizabeth L | Officer | Form 144 notice | 2,079 | $85k | Notice | SEC | |
| Feb 6, 2023 | Geary Richard S | Officer | Form 144 notice | 1,920 | $78k | Notice | SEC | |
| Feb 6, 2023 | Cadoret-Manier Onaiza | Officer | Form 144 notice | 1,451 | $59k | Notice | SEC | |
| Feb 6, 2023 | Bennett C Frank | Officer | Form 144 notice | 1,813 | $74k | Notice | SEC | |
| Feb 6, 2023 | O'Neil Patrick R. | Officer | Form 144 notice | 1,920 | $78k | Notice | SEC | |
| Jan 31, 2023 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 9,000 | $356k | 18.5% | Plan not stated | SEC |
| Jan 18, 2023 | Swayze Eric | EVP Research | Form 4 sale | 5,631 | $224k | 15.8% | Unusual | SEC |
| Jan 18, 2023 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Form 4 sale | 4,752 | $188k | 17.5% | Plan not stated | SEC |
| Jan 18, 2023 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 7,836 | $309k | 13.9% | Plan not stated | SEC |
| Jan 18, 2023 | Monia Brett P | Chief Executive Officer | Form 4 sale | 25,066 | $990k | 17.2% | Plan not stated | SEC |
| Jan 18, 2023 | Hougen Elizabeth L | EVP, Finance & CFO | Form 4 sale | 8,280 | $329k | 10.1% | Plan not stated | SEC |
| Jan 18, 2023 | Geary Richard S | EVP, Chief Development Officer | Form 4 sale | 7,873 | $312k | 10.0% | Plan not stated | SEC |
| Jan 18, 2023 | Cadoret-Manier Onaiza | EVP, Chf GL Pdt Str & Oper Ofc | Form 4 sale | 3,748 | $148k | 16.8% | Plan not stated | SEC |
| Jan 18, 2023 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 6,978 | $271k | 9.3% | Plan not stated | SEC |
| Jan 18, 2023 | Baroldi Joseph | EVP, Chief Business Officer | Form 4 sale | 375 | $15k | 30.6% | Unusual | SEC |
| Jan 18, 2023 | Schneider Eugene | Officer | Form 144 notice | 5,400 | $221k | Notice | SEC | |
| Jan 18, 2023 | Monia Brett P | Officer, Director | Form 144 notice | 24,000 | $984k | Notice | SEC | |
| Jan 18, 2023 | Geary Richard S | Officer | Form 144 notice | 9,000 | $369k | Notice | SEC | |
| Jan 18, 2023 | Swayze Eric | Officer | Form 144 notice | 6,500 | $267k | Notice | SEC | |
| Jan 18, 2023 | Cadoret-Manier Onaiza | Officer | Form 144 notice | 4,200 | $172k | Notice | SEC | |
| Jan 18, 2023 | O'Neil Patrick R. | Officer | Form 144 notice | 9,000 | $369k | Notice | SEC | |
| Jan 17, 2023 | Klein Joseph III | Director | Form 4 sale | 2,000 | $80k | 10.6% | Plan not stated | SEC |
| Sep 8, 2022 | Swayze Eric | EVP Research | Form 4 sale | 460 | $20k | 2.3% | Plan not stated | SEC |
| Aug 5, 2022 | Swayze Eric | EVP Research | Form 4 sale | 1 | $45 | 0.0% | Plan not stated | SEC |
| Jul 15, 2022 | Klein Joseph III | Director | Form 4 sale | 1,333 | $51k | 6.6% | Plan not stated | SEC |
| Apr 21, 2022 | Swayze Eric | EVP Research | Form 4 sale | 378 | $17k | 1.8% | Plan not stated | SEC |
| Apr 12, 2022 | O'Neil Patrick R. | EVP CLO & General Counsel | Form 4 sale | 6,792 | $272k | 16.4% | Plan not stated | SEC |
| Apr 1, 2022 | Monia Brett P | Chief Executive Officer | Form 4 sale | 355 | $13k | 0.4% | Plan not stated | SEC |
| Jul 15, 2021 | Klein Joseph III | Director | Form 4 sale | 4,334 | $153k | 19.3% | Unusual | SEC |
| Jun 23, 2021 | Berthelsen Spencer R | Director | Form 4 sale | 15,000 | $566k | 12.9% | Plan not stated | SEC |
| Jun 15, 2021 | Muto Frederick T | Director | Form 4 sale | 15,000 | $550k | 32.1% | Unusual | SEC |
| Mar 1, 2021 | Monia Brett P | Chief Executive Officer | Form 4 sale | 236 | $13k | 0.5% | Plan not stated | SEC |
| Jan 26, 2021 | Crooke Stanley T | Exec Chairman of the Board | Form 4 sale | 28,333 | $1.8M | 93.3% | Unusual | SEC |
| Jan 25, 2021 | O'Neil Patrick R. | EVP & General Counsel | Form 4 sale | 5,324 | $338k | 16.7% | Plan not stated | SEC |
| Jan 22, 2021 | Crooke Stanley T | Exec Chairman of the Board | Form 4 sale | 75,000 | $4.6M | 13.2% | Unusual | SEC |
| Jan 13, 2021 | Geary Richard S | EVP, Chief Development Offc | Form 4 sale | 141 | $8k | 0.5% | Plan not stated | SEC |
| Jan 5, 2021 | Swayze Eric | EVP, Research | Form 4 sale | 195 | $11k | 3.7% | Plan not stated | SEC |
| Dec 23, 2020 | Parshall B Lynne | Director | Form 4 sale | 10,000 | $600k | 14.8% | Plan not stated | SEC |
| Dec 17, 2020 | Crooke Stanley T | Exec Chairman of the Board | Form 4 sale | 40,407 | $2M | 99.6% | Unusual | SEC |
| Dec 7, 2020 | Crooke Stanley T | Exec Chairman of the Board | Form 4 sale | 11,000 | $568k | 1.7% | Plan not stated | SEC |
| Dec 4, 2020 | Monia Brett P | Chief Executive Officer | Form 4 sale | 23,840 | $1.2M | 45.2% | Unusual | SEC |
| Dec 4, 2020 | Bennett C Frank | Chief Scientific Officer | Form 4 sale | 7,947 | $406k | 19.7% | Plan not stated | SEC |
| Dec 2, 2020 | Bennett C Frank | Chief Scientific Officer | Form 4 sale | 7,053 | $362k | 17.8% | Plan not stated | SEC |
| Dec 2, 2020 | Monia Brett P | Chief Executive Officer | Form 4 sale | 21,160 | $1.1M | 42.3% | Unusual | SEC |
| Nov 25, 2020 | Hougen Elizabeth L | EVP, Finance & CFO | Form 4 sale | 21,680 | $1.1M | 40.0% | Unusual | SEC |
| Nov 25, 2020 | Crooke Stanley T | Exec Chairman of the Board | Form 4 sale | 12,990 | $650k | 86.5% | Unusual | SEC |
| Nov 25, 2020 | Geary Richard S | EVP, Development | Form 4 sale | 11,920 | $597k | 28.1% | Unusual | SEC |
| Nov 25, 2020 | Parshall B Lynne | Director | Form 4 sale | 3,590 | $180k | 5.1% | Plan not stated | SEC |
| Nov 24, 2020 | Crooke Stanley T | Exec Chairman of the Board | Form 4 sale | 14,690 | $738k | 90.3% | Unusual | SEC |
| Nov 24, 2020 | Hougen Elizabeth L | EVP, Finance & CFO | Form 4 sale | 23,320 | $1.2M | 41.8% | Unusual | SEC |
| Nov 24, 2020 | Geary Richard S | EVP, Development | Form 4 sale | 13,080 | $657k | 30.1% | Unusual | SEC |
| Nov 24, 2020 | Parshall B Lynne | Director | Form 4 sale | 3,910 | $196k | 5.5% | Plan not stated | SEC |
| Nov 3, 2020 | Bennett C Frank | Chief Scientific Officer | Form 4 sale | 15,000 | $702k | 31.6% | Unusual | SEC |
| Oct 20, 2020 | Klein Joseph III | Director | Form 4 sale | 2,889 | $135k | 17.3% | Plan not stated | SEC |
| Sep 22, 2020 | Crooke Stanley T | Exec Chairman of the Board | Form 4 sale | 52,000 | $2.6M | 7.4% | Plan not stated | SEC |
| Sep 1, 2020 | Monia Brett P | Chief Executive Officer | Form 4 sale | 314 | $17k | 1.1% | Plan not stated | SEC |
| Jun 25, 2020 | Castleman Breaux | Director | Form 4 sale | 10,000 | $600k | 39.7% | Unusual | SEC |
| Jun 25, 2020 | Bennett C Frank | EVP, Chief Scientific Officer | Form 4 sale | 15,000 | $897k | 31.7% | Unusual | SEC |
| Jun 25, 2020 | Crooke Stanley T | Exec Chairman of the Board | Form 4 sale | 14,914 | $890k | 88.1% | Unusual | SEC |
| Jun 23, 2020 | Berthelsen Spencer R | Director | Form 4 sale | 15,000 | $881k | 13.4% | Plan not stated | SEC |
| Jun 19, 2020 | Crooke Stanley T | Exec Chairman of the Board | Form 4 sale | 27,000 | $1.6M | 61.5% | Unusual | SEC |
| Mar 25, 2020 | Crooke Stanley T | Exec Chairman of the Board | Form 4 sale | 16,000 | $752k | 27.6% | Unusual | SEC |
| Mar 19, 2020 | Crooke Stanley T | Exec Chairman of the Board | Form 4 sale | 16,000 | $723k | 22.1% | Plan not stated | SEC |
| Mar 17, 2020 | Crooke Stanley T | Exec Chairman of the Board | Form 4 sale | 20,390 | $912k | 22.2% | Plan not stated | SEC |
| Feb 10, 2020 | O'Neil Patrick R. | SVP & General Counsel | Form 4 sale | 3,882 | $231k | 15.8% | Plan not stated | SEC |
| Jan 2, 2020 | Monia Brett P | Chief Executive Officer | Form 4 sale | 173 | $10k | 1.1% | Plan not stated | SEC |
| Dec 23, 2019 | Klein Joseph III | Director | Form 4 sale | 1,000 | $62k | 7.3% | Plan not stated | SEC |
| Dec 16, 2019 | Klein Joseph III | Director | Form 4 sale | 1,000 | $65k | 7.3% | Plan not stated | SEC |
| Dec 9, 2019 | Klein Joseph III | Director | Form 4 sale | 1,000 | $64k | 7.3% | Plan not stated | SEC |
| Dec 4, 2019 | Hougen Elizabeth L | SVP, Finance & CFO | Form 4 sale | 4,566 | $297k | 18.5% | Plan not stated | SEC |
| Dec 4, 2019 | Geary Richard S | SVP, Development | Form 4 sale | 10,000 | $650k | 31.7% | Unusual | SEC |
| Dec 2, 2019 | Klein Joseph III | Director | Form 4 sale | 1,000 | $64k | 7.3% | Plan not stated | SEC |
| Dec 2, 2019 | Geary Richard S | SVP, Development | Form 4 sale | 5,000 | $325k | 18.8% | Plan not stated | SEC |
| Nov 25, 2019 | Klein Joseph III | Director | Form 4 sale | 812 | $51k | 6.0% | Plan not stated | SEC |
| Nov 25, 2019 | Hougen Elizabeth L | SVP, Finance & CFO | Form 4 sale | 4,000 | $250k | 16.6% | Plan not stated | SEC |
| Nov 20, 2019 | Klein Joseph III | Director | Form 4 sale | 2,000 | $120k | 12.9% | Plan not stated | SEC |
| Nov 20, 2019 | Monia Brett P | COO & SVP, Translational Med | Form 4 sale | 5,776 | $347k | 26.0% | Unusual | SEC |
| Nov 19, 2019 | Hougen Elizabeth L | SVP, Finance & CFO | Form 4 sale | 4,000 | $235k | 16.6% | Plan not stated | SEC |
| Aug 21, 2019 | Crooke Stanley T | Chairman and CEO | Form 4 sale | 22,000 | $1.6M | 24.0% | Plan not stated | SEC |
| Jul 18, 2019 | Crooke Stanley T | Chairman & CEO | Form 4 sale | 10,000 | $703k | 12.6% | Plan not stated | SEC |
| Jul 2, 2019 | Monia Brett P | Chief Operating Officer | Form 4 sale | 210 | $14k | 0.9% | Plan not stated | SEC |
| Jun 24, 2019 | Berthelsen Spencer R | Director | Form 4 sale | 15,000 | $955k | 13.7% | Plan not stated | SEC |
| Jun 4, 2019 | Muto Frederick T | Director | Form 4 sale | 15,000 | $979k | 60.5% | Unusual | SEC |
| May 6, 2019 | Muto Frederick T | Director | Form 4 sale | 8,000 | $582k | 45.0% | Unusual | SEC |
| Apr 29, 2019 | Parshall B Lynne | Director | Form 4 sale | 50,000 | $3.8M | 48.7% | Unusual | SEC |
| Apr 16, 2019 | Crooke Stanley T | Chairman and CEO | Form 4 sale | 32,000 | $2.7M | 31.5% | Unusual | SEC |
| Apr 8, 2019 | Geary Richard S | SVP, Development | Form 4 sale | 46,240 | $3.9M | 68.3% | Unusual | SEC |
| Apr 5, 2019 | O'Neil Patrick R. | SVP Legal & General Counsel | Form 4 sale | 49,528 | $4.2M | 74.8% | Unusual | SEC |
| Mar 19, 2019 | Wender Joseph H | Director | Form 4 sale | 10,000 | $796k | 14.5% | Plan not stated | SEC |
| Mar 18, 2019 | O'Neil Patrick R. | SVP Legal & General Counsel | Form 4 sale | 28,800 | $2.3M | 59.4% | Unusual | SEC |
| Mar 12, 2019 | Parshall B Lynne | Director | Form 4 sale | 8,334 | $625k | 13.7% | Plan not stated | SEC |
| Feb 27, 2019 | Parshall B Lynne | Director | Form 4 sale | 8,333 | $583k | 13.7% | Plan not stated | SEC |
| Feb 27, 2019 | O'Neil Patrick R. | SVP Legal & General Counsel | Form 4 sale | 26,800 | $1.8M | 57.7% | Unusual | SEC |
| Feb 26, 2019 | Crooke Stanley T | Chairman and CEO | Form 4 sale | 77,000 | $4.7M | 52.5% | Unusual | SEC |
| Feb 13, 2019 | Crooke Stanley T | Chairman and CEO | Form 4 sale | 46,904 | $2.8M | 40.2% | Unusual | SEC |
| Feb 13, 2019 | Geary Richard S | SVP, Development | Form 4 sale | 999 | $60k | 4.5% | Plan not stated | SEC |
| Feb 12, 2019 | O'Neil Patrick R. | SVP Legal & General Counsel | Form 4 sale | 275 | $16k | 1.4% | Plan not stated | SEC |
| Feb 5, 2019 | O'Neil Patrick R. | SVP Legal & General Counsel | Form 4 sale | 19,600 | $1.2M | 49.9% | Unusual | SEC |
| Feb 1, 2019 | Bennett C Frank | SVP, Antisense Research | Form 4 sale | 9,013 | $525k | 26.9% | Unusual | SEC |
| Jan 3, 2019 | O'Neil Patrick R. | SVP Legal & General Counsel | Form 4 sale | 4,400 | $241k | 23.2% | Unusual | SEC |
| Jan 2, 2019 | Monia Brett P | Chief Operating Officer | Form 4 sale | 214 | $11k | 1.3% | Plan not stated | SEC |
| Dec 19, 2018 | Hougen Elizabeth L | SVP, Finance & CFO | Form 4 sale | 4,063 | $211k | 21.6% | Plan not stated | SEC |
| Nov 23, 2018 | Monia Brett P | Chief Operating Officer | Form 4 sale | 34,000 | $1.9M | 68.2% | Unusual | SEC |
| Nov 1, 2018 | Bennett C Frank | SVP, Antisense Research | Form 4 sale | 12,500 | $619k | 39.2% | Unusual | SEC |
| Aug 27, 2018 | Monia Brett P | Chief Operating Officer | Form 4 sale | 16,493 | $891k | 51.0% | Unusual | SEC |
| Aug 8, 2018 | Bennett C Frank | SVP, Antisense Research | Form 4 sale | 12,500 | $563k | 39.2% | Unusual | SEC |
| Jul 24, 2018 | Monia Brett P | Chief Operating Officer | Form 4 sale | 156 | $7k | 1.0% | Plan not stated | SEC |
| Jun 25, 2018 | Berthelsen Spencer R | Director | Form 4 sale | 15,000 | $635k | 14.1% | Plan not stated | SEC |
| May 31, 2018 | Muto Frederick T | Director | Form 4 sale | 15,000 | $697k | 67.8% | Unusual | SEC |
| May 11, 2018 | Bennett C Frank | SVP, Antisense Research | Form 4 sale | 12,500 | $563k | 39.5% | Unusual | SEC |
| May 11, 2018 | Wender Joseph H | Director | Form 4 sale | 15,000 | $680k | 29.3% | Unusual | SEC |
| Apr 17, 2018 | Crooke Stanley T | Chairman and CEO | Form 4 sale | 13,962 | $620k | 21.3% | Plan not stated | SEC |
| Mar 29, 2018 | Klein Joseph III | Director | Form 4 sale | 2,000 | $92k | 16.8% | Plan not stated | SEC |
| Mar 15, 2018 | Klein Joseph III | Director | Form 4 sale | 2,000 | $102k | 16.8% | Plan not stated | SEC |
| Mar 12, 2018 | O'Neil Patrick R. | SVP Legal & General Counsel | Form 4 sale | 1,000 | $55k | 6.5% | Plan not stated | SEC |
| Feb 28, 2018 | Klein Joseph III | Director | Form 4 sale | 3,000 | $156k | 23.2% | Plan not stated | SEC |
| Feb 15, 2018 | Klein Joseph III | Director | Form 4 sale | 3,000 | $147k | 23.2% | Plan not stated | SEC |
| Jan 29, 2018 | O'Neil Patrick R. | SVP Legal & General Counsel | Form 4 sale | 355 | $20k | 2.4% | Plan not stated | SEC |
| Jan 25, 2018 | O'Neil Patrick R. | SVP Legal & General Counsel | Form 4 sale | 645 | $35k | 4.3% | Plan not stated | SEC |
| Jan 16, 2018 | Hougen Elizabeth L | SVP, Finance & CFO | Form 4 sale | 2,724 | $141k | 15.8% | Plan not stated | SEC |
| Jan 16, 2018 | Klein Joseph III | Director | Form 4 sale | 3,000 | $158k | 23.2% | Plan not stated | SEC |
| Jan 16, 2018 | Geary Richard S | SVP, Development | Form 4 sale | 2,723 | $141k | 14.0% | Plan not stated | SEC |
| Jan 16, 2018 | Parshall B Lynne | Director | Form 4 sale | 5,986 | $310k | 13.6% | Plan not stated | SEC |
| Jan 16, 2018 | O'Neil Patrick R. | SVP, Legal & General Counsel | Form 4 sale | 2,697 | $140k | 15.7% | Plan not stated | SEC |
| Jan 16, 2018 | Boyce Sarah | Chief Business Officer | Form 4 sale | 2,196 | $114k | 19.7% | Plan not stated | SEC |
| Jan 16, 2018 | Bennett C Frank | SVP, Antisense Research | Form 4 sale | 2,696 | $140k | 12.4% | Plan not stated | SEC |
| Jan 16, 2018 | Monia Brett P | COO | Form 4 sale | 2,821 | $146k | 15.2% | Unusual | SEC |
| Jan 15, 2018 | Crooke Stanley T | Chairman and CEO | Form 4 sale | 16,549 | $857k | 24.2% | Plan not stated | SEC |
| Jan 8, 2018 | Crooke Stanley T | Chairman and CEO | Form 4 sale | 11,000 | $572k | 22.4% | Plan not stated | SEC |
| Jan 3, 2018 | Crooke Stanley T | Chairman and CEO | Form 4 sale | 22,000 | $1.1M | 36.7% | Unusual | SEC |
| Jan 2, 2018 | Monia Brett P | SVP, Antisense Drug Discovery | Form 4 sale | 163 | $8k | 1.4% | Plan not stated | SEC |
| Dec 29, 2017 | Klein Joseph III | Director | Form 4 sale | 3,000 | $152k | 23.2% | Plan not stated | SEC |
| Dec 15, 2017 | Klein Joseph III | Director | Form 4 sale | 3,000 | $155k | 23.2% | Plan not stated | SEC |
| Dec 15, 2017 | Hougen Elizabeth L | SVP, Finance & CFO | Form 4 sale | 5,000 | $263k | 32.5% | Unusual | SEC |
| Dec 4, 2017 | Hougen Elizabeth L | SVP, Finance & CFO | Form 4 sale | 4,000 | $228k | 27.8% | Unusual | SEC |
| Dec 1, 2017 | O'Neil Patrick R. | SVP, Legal & General Counsel | Form 4 sale | 1,000 | $56k | 8.7% | Plan not stated | SEC |
| Nov 30, 2017 | Klein Joseph III | Director | Form 4 sale | 3,000 | $161k | 23.2% | Plan not stated | SEC |
| Nov 29, 2017 | Hougen Elizabeth L | SVP, Finance & CFO | Form 4 sale | 6,000 | $318k | 36.6% | Unusual | SEC |
| Nov 16, 2017 | Hougen Elizabeth L | SVP, Finance & CFO | Form 4 sale | 7,000 | $380k | 40.2% | Unusual | SEC |
| Nov 15, 2017 | Klein Joseph III | Director | Form 4 sale | 2,250 | $121k | 24.0% | Plan not stated | SEC |
| Nov 13, 2017 | Klein Joseph III | Director | Form 4 sale | 3,000 | $166k | 29.6% | Unusual | SEC |
| Nov 1, 2017 | O'Neil Patrick R. | SVP, Legal & General Counsel | Form 4 sale | 1,000 | $58k | 8.7% | Plan not stated | SEC |
| Oct 18, 2017 | Bennett C Frank | SVP, Antisense Research | Form 4 sale | 12,250 | $796k | 44.9% | Unusual | SEC |
| Oct 18, 2017 | Parshall B Lynne | COO | Form 4 sale | 16,118 | $1M | 38.5% | Unusual | SEC |
| Oct 13, 2017 | Crooke Stanley T | Chairman and CEO | Form 4 sale | 16,500 | $981k | 30.3% | Unusual | SEC |
| Oct 13, 2017 | Geary Richard S | SVP, Development | Form 4 sale | 8,268 | $496k | 40.1% | Unusual | SEC |
| Oct 5, 2017 | O'Neil Patrick R. | SVP, Legal & General Counsel | Form 4 sale | 1,000 | $55k | 8.7% | Plan not stated | SEC |
| Oct 4, 2017 | Crooke Stanley T | Chairman and CEO | Form 4 sale | 27,500 | $1.5M | 42.0% | Unusual | SEC |
| Sep 6, 2017 | O'Neil Patrick R. | SVP, Legal and General Counsel | Form 4 sale | 1,000 | $55k | 8.7% | Plan not stated | SEC |
| Jul 24, 2017 | Bennett C Frank | SVP, Antisense Research | Form 4 sale | 10,000 | $593k | 39.9% | Unusual | SEC |
| Jul 20, 2017 | Crooke Stanley T | Chairman and CEO | Form 4 sale | 11,000 | $609k | 22.4% | Plan not stated | SEC |